AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24899329 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper arch vs lower arch
Number of subjects: 194
Study 24899329 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of missing teeth
Number of subjects: 194
Study 20962162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-glycemic load diet
Number of subjects: 46
Study 20962162 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 46
Study 18800990 — intervention group
Group type: EXPERIMENTAL
Intervention: PA counseling over the telephone and through mailed materials
Number of subjects: 357
Study 18800990 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PA from above threshold to below threshold
Number of subjects: 357
Study 18800990 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PA from below threshold to above threshold
Number of subjects: 357
Study 15690666 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed hemorrhoidectomy
Number of subjects: 80
Study 15690666 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy
Number of subjects: 80
Study 12734746 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 6 months
Number of subjects: 37
Study 12734746 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 2 years
Number of subjects: 37
Study 12734746 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH) at a dosage of 28 IU/m² per week for 4 years
Number of subjects: 37
Study 10374214 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day tibolone continuously (n = 27; group T)
Number of subjects: 76
Study 10374214 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day conjugated equine estrogen plus 2.5 mg/day of medroxyprogesterone (n = 25; group E-P)
Number of subjects: 76
Study 10374214 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 24; group C)
Number of subjects: 76
Study 8927658 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI 204,636
Number of subjects: 0
Study 8927658 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 0
Study 8927658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2071784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized orchard grass-pollen extract or standardized mixed-pollen extract (specific immunotherapy)
Number of subjects: 70
Study 2071784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 6650449 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention advising to change dietary habits (mainly reduce saturated fat)
Number of subjects: 42
Study 6650449 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 men)
Number of subjects: 42
Study 30686102 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression and fusion surgery
Number of subjects: 68
Study 31106551 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% levobupivacaine
Number of subjects: 161
Study 31106551 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625% ropivacaine
Number of subjects: 161
Study 31106551 — intervention group
Group type: COMPARATOR
Intervention: no PCEA
Number of subjects: 161
Study 29072019 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal acupuncture combined with warm needling
Number of subjects: 86
Study 29072019 — intervention group
Group type: COMPARATOR
Intervention: Warm needling (control group)
Number of subjects: 86
Study 25471256 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation (group-based sessions conducted twice a week for 9 weeks)
Number of subjects: 68
Study 25471256 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 68
Study 23432476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with plasmapheresis
Number of subjects: 20
Study 23432476 — intervention group
Group type: COMPARATOR
Intervention: Rituximab without plasmapheresis
Number of subjects: 20
Study 22009807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1µg/kg administered three minutes before anesthesia induction
Number of subjects: 60
Study 22009807 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fentanyl)
Number of subjects: 60
Study 22009807 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl 1µg/kg
Number of subjects: 60
Study 19147455 — intervention group
Group type: EXPERIMENTAL
Intervention: Strict metabolic control by insulin (I-group; n = 21)
Number of subjects: 39
Study 19147455 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose lowering agents (O-group; n = 18)
Number of subjects: 39
Study 17760290 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective thermal inserts (RTI) and armor with supplementary irradiance (RA+I)
Number of subjects: 4
Study 17760290 — intervention group
Group type: COMPARATOR
Intervention: Plain armor with supplementary irradiance (PA+I)
Number of subjects: 4
Study 17760290 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective thermal inserts (RTI) and armor with no supplementary irradiance (RA-I)
Number of subjects: 4
Study 17760290 — intervention group
Group type: COMPARATOR
Intervention: Plain armor with no supplementary irradiance (PA-I)
Number of subjects: 4
Study 15150623 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin (E) 80 mg/m² + Paclitaxel (T) 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Number of subjects: 234
Study 15150623 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m² (3 h infusion), every 21 days for 4-6 cycles
Number of subjects: 234
Study 15150623 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidoxorubicin + Paclitaxel (ET)
Number of subjects: 234
Study 15150623 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (T)
Number of subjects: 234
Study 11095453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg x day GH (n = 30)
Number of subjects: 99
Study 11095453 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg x day GH (n = 29)
Number of subjects: 99
Study 11095453 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 99
Study 10178482 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring strips prescribed
Number of subjects: 115
Study 10178482 — intervention group
Group type: COMPARATOR
Intervention: No blood glucose monitoring strips prescribed
Number of subjects: 115
Study 7902200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment teaching module applied three hours per week for two to three months
Number of subjects: 20
Study 7902200 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment teaching module
Number of subjects: 20
Study 7902200 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education module)
Number of subjects: 20
Study 3516921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic ioxaglate (Hexabrix‐20)
Number of subjects: 0
Study 3516921 — intervention group
Group type: COMPARATOR
Intervention: Renografin‐76
Number of subjects: 0
Study 30390355 — intervention group
Group type: EXPERIMENTAL
Intervention: Processed diets (PEL, EXTL, EXTH)
Number of subjects: 30
Study 28343596 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide liner with RMGI restorations (Control group)
Number of subjects: 98
Study 28343596 — intervention group
Group type: EXPERIMENTAL
Intervention: No calcium hydroxide liner with RMGI restorations (Test group)
Number of subjects: 98
Study 28343596 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without calcium hydroxide liner)
Number of subjects: 98
Study 25794779 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (or clindamycin) given from one hour before operation until 3 days postoperatively
Number of subjects: 207
Study 25794779 — intervention group
Group type: COMPARATOR
Intervention: Placebo given at the same time as the antibiotic
Number of subjects: 207
Study 23434109 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methionine (100 mg/kg)
Number of subjects: 30
Study 23434109 — intervention group
Group type: COMPARATOR
Intervention: Water consumption
Number of subjects: 30
Study 21242339 — intervention group
Group type: EXPERIMENTAL
Intervention: Solegg® and Solegg® Fine compressive stockings (15‐20 mmHg)
Number of subjects: 20
Study 21242339 — intervention group
Group type: COMPARATOR
Intervention: Usual non‐compressive stockings (controls)
Number of subjects: 20
Study 20396717 — intervention group
Group type: EXPERIMENTAL
Intervention: artrofoon
Number of subjects: 30
Study 20396717 — intervention group
Group type: COMPARATOR
Intervention: nonsteroidal antiinflammatory preparations (NSAIDs)
Number of subjects: 30
Study 17568028 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Number of subjects: 245
Study 17568028 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 245
Study 17568028 — intervention group
Group type: EXPERIMENTAL
Intervention: Anidulafungin (after removing data from the site enrolling the largest number of patients)
Number of subjects: 245
Study 17568028 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (after removing data from the site enrolling the largest number of patients)
Number of subjects: 245
Study 15339439 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieyu Huoxue Decoction
Number of subjects: 54
Study 15339439 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 54
Study 15339439 — intervention group
Group type: COMPARATOR
Intervention: Depression control group
Number of subjects: 54
Study 11434828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d
Number of subjects: 2884
Study 11434828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2884
Study 11434828 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/d (secondary prevention cohort)
Number of subjects: 2884
Study 10188716 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐cadherin expression in normal and metaplastic OSE
Number of subjects: 0
Study 10188716 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐cadherin expression in OSE
Number of subjects: 0
Study 10188716 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐cadherin expression in OSE
Number of subjects: 0
Study 10188716 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal differentiation in (pre)‐neoplastic tissues
Number of subjects: 0
Study 7778840 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 500 mg
Number of subjects: 419
Study 7778840 — intervention group
Group type: EXPERIMENTAL
Intervention: Famciclovir 750 mg
Number of subjects: 419
Study 7778840 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 2337520 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.05% tretinoin
Number of subjects: 18
Study 2337520 — intervention group
Group type: COMPARATOR
Intervention: Placebo base cream
Number of subjects: 18
Study 504666 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/50 ml of Xylocaine
Number of subjects: 0
Study 504666 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/50 ml of Xylocaine
Number of subjects: 0
Study 504666 — intervention group
Group type: COMPARATOR
Intervention: Plain contrast medium
Number of subjects: 0
Study 31424303 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontrast axial 3D T1-weighted imaging
Number of subjects: 12
Study 31424303 — intervention group
Group type: COMPARATOR
Intervention: Contrast-enhanced axial 3D T1-weighted imaging
Number of subjects: 12
Study 31424303 — intervention group
Group type: COMPARATOR
Intervention: Comparison of noncontrast to contrast-enhanced imaging
Number of subjects: 12
Study 28782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation with Large Changes
Number of subjects: 599
Study 28782918 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 599
Study 28782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Regulation with Small Changes
Number of subjects: 599
Study 28782918 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Change
Number of subjects: 599
Study 25388480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training after training phase
Number of subjects: 102
Study 25388480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training basic phase
Number of subjects: 102
Study 25388480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training after-training phase
Number of subjects: 102
Study 25388480 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat Application Tourniquet (CAT) training eyes-closed phase
Number of subjects: 102
Study 23437789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day of red grape seed extract (RGSE)
Number of subjects: 52
Study 23437789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 19909499 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (one gram twice daily)
Number of subjects: 11
Study 19909499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16739840 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife therapy
Number of subjects: 100
Study 16739840 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 100
Study 14644401 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistant subjects (IR)
Number of subjects: 91
Study 14644401 — intervention group
Group type: COMPARATOR
Intervention: Insulin sensitive subjects (Control)
Number of subjects: 91
Study 10711490 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-thumb method
Number of subjects: 209
Study 10711490 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-finger method
Number of subjects: 209
Study 8647966 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychologic intervention (seven individual psychotherapy sessions over 12 weeks)
Number of subjects: 51
Study 8647966 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychologic intervention)
Number of subjects: 51
Study 1524160 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40
Study 1524160 — intervention group
Group type: COMPARATOR
Intervention: Retrobulbar Anesthesia (RB)
Number of subjects: 40
Study 6654626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids plus vitamin A (3 X 50,000 U orally)
Number of subjects: 60
Study 6654626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids plus vitamin A plus cyproheptadine (3 X 4 mg orally)
Number of subjects: 60
Study 6654626 — intervention group
Group type: COMPARATOR
Intervention: Antacids only
Number of subjects: 60
Study 3511867 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized axial tomography (CAT) scans
Number of subjects: 100
Study 3511867 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical liver function tests (alkaline phosphatase, lactic dehydrogenase, carcinoembryonic antigen)
Number of subjects: 100
Study 3511867 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CAT scans and biochemical tests
Number of subjects: 100
Study 29467022 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 0
Study 29467022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0
Study 27450776 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive symptoms of psychosis (hallucinations and delusions)
Number of subjects: 1460
Study 27450776 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms of depression
Number of subjects: 1460
Study 27450776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hopelessness
Number of subjects: 1460
Study 24925372 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoxaparin subcutaneously once daily
Number of subjects: 266
Study 24925372 — intervention group
Group type: COMPARATOR
Intervention: 40 mg enoxaparin subcutaneously once daily
Number of subjects: 266
Study 22414236 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral prevention program
Number of subjects: 173
Study 22414236 — intervention group
Group type: COMPARATOR
Intervention: Educational brochure control condition
Number of subjects: 173
Study 19449224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF) nasal spray, 200 microg for 3 months
Number of subjects: 100
Study 19449224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 18690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal screening offered
Number of subjects: 0
Study 18690005 — intervention group
Group type: COMPARATOR
Intervention: No prenatal screening offered (Control)
Number of subjects: 0
Study 18690005 — intervention group
Group type: EXPERIMENTAL
Intervention: Decliners of the screening test
Number of subjects: 0
Study 15632339 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary PIGF concentrations in women with preeclampsia
Number of subjects: 240
Study 15632339 — intervention group
Group type: COMPARATOR
Intervention: Urinary PIGF concentrations in normotensive controls
Number of subjects: 240
Study 15632339 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of control PIGF concentrations (<118 pg/mL)
Number of subjects: 240
Study 12745724 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ephedrine 50 mg
Number of subjects: 60
Study 12745724 — intervention group
Group type: COMPARATOR
Intervention: Only premedication (control)
Number of subjects: 60
Study 12745724 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental ephedrine (3 mg)
Number of subjects: 60
Study 12745724 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.5 mg)
Number of subjects: 60
Study 11206014 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic therapy to passivate plaque for at least 24 hours
Number of subjects: 0
Study 11206014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparins and glycoprotein IIb/IIIa inhibitors
Number of subjects: 0
Study 8645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 200 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 400 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble ibuprofen 600 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen tablets 200 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen tablets 400 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen tablets 600 mg
Number of subjects: 148
Study 8645662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 1346564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.075 mg orally, at baseline and after 2 hours if heart rate did not decrease by at least 20%
Number of subjects: 18
Study 1346564 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 18
Study 1346564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 18
Study 1346564 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and Control
Number of subjects: 18
Study 6302650 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 106
Study 6302650 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (200 mg three times daily and 400 mg at night)
Number of subjects: 106
Study 31168411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 10 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 15 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 1 mg, 5 mg, 10 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosdagrocorat 1 mg, 5 mg, 10 mg, 15 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 5 mg
Number of subjects: 323
Study 31168411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 323
Study 29541895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual observer group (experienced nurse participation)
Number of subjects: 587
Study 29541895 — intervention group
Group type: COMPARATOR
Intervention: Single observer group (experienced colonoscopist alone)
Number of subjects: 587
Study 29541895 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 587
Study 26531829 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicorandil
Number of subjects: 52
Study 26531829 — intervention group
Group type: COMPARATOR
Intervention: Nitrate
Number of subjects: 52
Study 23868159 — intervention group
Group type: EXPERIMENTAL
Intervention: Operators' evaluation of angiographic appearance immediately after embolization
Number of subjects: 434
Study 23868159 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory evaluation of angiographic appearance immediately after embolization
Number of subjects: 434
Study 23868159 — intervention group
Group type: EXPERIMENTAL
Intervention: Operators' evaluation of angiographic appearance at follow-up
Number of subjects: 434
Study 23868159 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory evaluation of angiographic appearance at follow-up
Number of subjects: 434
Study 23868159 — intervention group
Group type: EXPERIMENTAL
Intervention: Operators' overall evaluation of unfavorable angiographic appearance
Number of subjects: 434
Study 23868159 — intervention group
Group type: COMPARATOR
Intervention: Core laboratory's overall evaluation of unfavorable angiographic appearance
Number of subjects: 434
Study 22365462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Teens program (12-week computerized cognitive-behavioral therapy program for anxiety management)
Number of subjects: 43
Study 22365462 — intervention group
Group type: COMPARATOR
Intervention: Wait list (control group)
Number of subjects: 43
Study 22365462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool Teens program
Number of subjects: 43
Study 19481279 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (low dose: 5 mg)
Number of subjects: 28